---
id: 133
title: HIV Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP)
category: organisms
subcategory: viruses
tags: [PrEP, PEP, HIV-prevention, Truvada, Descovy, cabotegravir]
difficulty: medium
---

## Question

How are PrEP and PEP used for HIV prevention? Use the **"PrEP = Daily Oral or Injectable Q2M, PEP = 3-Drug Within 72h"** framework.

## Answer

### **Pre-Exposure Prophylaxis (PrEP):**

**Indications (High-Risk Individuals):**
- **MSM** with condomless anal sex or recent STI
- **Heterosexual** with HIV+ partner or high-risk partner
- **IVDU** (injection drug users)
- **Serodiscordant couples** (one partner HIV+, one HIV-)
- **Commercial sex workers**

**Regimens:**

| Regimen | Dosing | Efficacy | Notes |
|---------|--------|----------|-------|
| **TDF/FTC (Truvada)** | **1 tablet daily** | **>99%** (if adherent) | **Most data**, **approved for all at-risk** |
| **TAF/FTC (Descovy)** | **1 tablet daily** | **>99%** (if adherent) | **NOT for receptive vaginal/frontal sex** (insufficient data), less renal/bone toxicity than TDF |
| **Cabotegravir (Apretude)** | **600mg IM q2 months** (after 2 monthly loading doses) | **>99%** (superior to oral) | **Injectable**, **highest efficacy**, adherence advantages |

**On-Demand PrEP (2-1-1):**
- **Dosing:** **2 tablets 2-24h before sex** → **1 tablet 24h after first dose** → **1 tablet 48h after first dose**
- **Efficacy:** 86% (MSM only, NOT recommended for vaginal/frontal sex)
- **Less common** (daily PrEP preferred in US guidelines)

### **PrEP Monitoring:**

**Baseline:**
- **HIV test** (4th generation Ag/Ab) - **rule out HIV** before starting
- **Hepatitis B serology** (TDF/FTC treats HBV, risk of flare if stopped)
- **STI screening** (gonorrhea, chlamydia, syphilis)
- **CrCl** (renal function), **pregnancy test**

**Follow-Up:**
- **Every 3 months:** HIV test, STI screening, adherence counseling
- **Every 6 months:** CrCl (if on TDF)
- **Every 12 months:** Hepatitis C screening (MSM, IVDU)

**Stopping PrEP:**
- **Oral PrEP:** Continue for **7 days** after last potential exposure (MSM) OR **28 days** (vaginal/frontal sex)
- **Injectable:** Protected for **2+ months** after last injection

### **Post-Exposure Prophylaxis (PEP):**

**Indications:**
- **Occupational:** Needlestick, splash to mucous membranes (healthcare workers)
- **Non-Occupational:** Condomless sex with HIV+ or unknown-status partner, sexual assault, needle-sharing

**Timing:**
- **Start within 72 hours** of exposure (ideally within 2-4 hours)
- **NOT indicated** if >72 hours (low efficacy)

**Regimen (3-Drug, 28 Days):**
- **Preferred:** **TDF/FTC + dolutegravir** (or **TDF/FTC + raltegravir**)
  - **TDF/FTC (Truvada) 1 tablet daily** + **dolutegravir 50mg daily** × 28 days
- **Alternative:** **TAF/FTC + dolutegravir** OR **TDF/FTC + darunavir/ritonavir**

**Monitoring:**
- **Baseline:** HIV test (4th gen Ag/Ab), hepatitis B/C, STI screening, CrCl, pregnancy test
- **4-6 weeks:** HIV test (detect seroconversion)
- **3 months:** HIV test (final)

**Efficacy:**
- **81% reduction** in HIV transmission (if started within 72h and completed full 28 days)

## Key Points

### **PrEP Efficacy and Adherence:**
- **>99% effective** if taken daily (oral) or every 2 months (injectable)
- **Adherence critical:** 4 doses/week = 96% protection (MSM), 6-7 doses/week needed for vaginal/frontal sex
- **Injectable cabotegravir** superior to oral (removes adherence barrier)

### **PrEP and Kidney Function:**
- **TDF:** Can cause **renal toxicity** (Fanconi syndrome, AKI) - monitor CrCl every 6 months
- **TAF:** **Less renal toxicity** than TDF (preferred if CrCl concerns)
- **Contraindication:** CrCl <60 mL/min (TDF), CrCl <30 mL/min (TAF)

### **Hepatitis B Considerations (PrEP):**
- **TDF/FTC treats HBV** (dual benefit if HBV+)
- **Risk of HBV flare** if stopped abruptly in HBV+ patients
- **If HBV+ and stopping PrEP:** Monitor LFTs, consider HBV-specific therapy

### **False Starts (PrEP):**
- **Rule out acute HIV** before starting PrEP
- **Acute HIV:** HIV RNA+ but Ag/Ab- (window period)
- **If suspected acute HIV:** Hold PrEP, repeat HIV test in 1-2 weeks, consider HIV RNA

### **PEP vs PrEP:**
- **PEP:** **Post-exposure**, 3-drug regimen × 28 days, within 72h
- **PrEP:** **Pre-exposure**, ongoing prophylaxis (daily or Q2M), before exposure
- **Transition:** After completing PEP, consider **starting PrEP** if ongoing high-risk behavior

### **Clinical Pearls:**
- **PrEP (daily):** TDF/FTC (Truvada) 1 tablet daily (>99% effective if adherent)
- **PrEP (injectable):** Cabotegravir 600mg IM q2 months (highest efficacy, best adherence)
- **PEP:** TDF/FTC + dolutegravir × 28 days (start within 72h)
- **Monitor PrEP:** HIV test every 3 months, CrCl every 6 months (if TDF)
- **TAF/FTC NOT for receptive vaginal/frontal sex** (insufficient data)
- **Rule out acute HIV** before starting PrEP (HIV RNA if suspected)

## Sources

- [CDC: PrEP Guidelines 2024]
- [DHHS: PEP Guidelines 2024]

## Media

N/A
